Moreover, AT56 enhanced the inhibitory role of Sorafenib on the bioluminescence and Ki67 expression of PTCL cells in vivo (Supplementary Fig. S4D–E). This evidence concerns the gene MKI67 and mature T-cell and NK-cell non-Hodgkin lymphoma.